Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ: NTRA) in the s

The billionaire has good reasons to like this genetic testing leader.

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testin

Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

ADAR1 Capital Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the unde

Avala Global LP acquired a new stake in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, accord

Duquesne Family Office has beefed up its healthcare holdings.

Callan Family Office LLC bought a new position in Natera, Inc. (NASDAQ: NTRA) during the second quar

Bank of Nova Scotia purchased a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the undefined

Brandywine Managers LLC acquired a new stake in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter

Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain wh

Bank of New York Mellon Corp acquired a new position in Natera, Inc. (NASDAQ: NTRA) in the second qu

Shares of Natera, Inc. (NASDAQ: NTRA - Get Free Report) have received a consensus rating of "Moderat

The hedge fund legend has bet much of the family office on this one diagnostics company.

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized b

Quarterly 13F disclosures offer individual investors an irreplaceable window into the playbooks of m

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and charac

Empowered Funds LLC decreased its position in shares of Natera, Inc. (NASDAQ: NTRA) by 65.9% during

Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-qua

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raise

Stephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and rai

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ invest

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price targe

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the p

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue out

JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the

Wells Fargo analyst Evan Stampler maintains Natera (NASDAQ:NTRA) with a Equal-Weight and raises t

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market

Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.740 billion-$2.820 billion to $2.850 billio

Natera (NASDAQ:NTRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.85% on an annualized b

The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval i

The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), f

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the pr

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises t

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar